mRNA Vaccines for COVID-19
Not yet recruiting at 148 trial locations
MW
Overseen ByModerna WeCare Team
Age: 18 - 65
Sex: Any
Trial Phase: Phase 4
Sponsor: ModernaTX, Inc.
Prior Safety DataThis treatment has passed at least one previous human trial
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.
Are You a Good Fit for This Trial?
This clinical trial is for adults aged 50 to 64 who are not at high risk for severe COVID-19. Participants will be testing two variant formulations of mRNA vaccines, aiming to see how well they work and their safety profile.Inclusion Criteria
I am healthy with no conditions that increase my COVID-19 risks, confirmed by medical tests.
Exclusion Criteria
Receipt of any of the following: COVID-19 vaccine within 3 months prior to enrollment, Any licensed non COVID-19 vaccine within 28 days before or planned receipt within 28 days after the study intervention, except an influenza vaccine, which may be given 14 days before or after receipt of the study intervention, Corticosteroids at ≥10 milligrams (mg)/day of prednisone or equivalent for >14 days in total within 90 days prior to Day 1 or is anticipating the need for corticosteroids at any time during the study, Systemic immunosuppressive treatment within 180 days prior to the Screening or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study
Has donated ≥450 mL of blood products within 28 days prior to the Screening Visit or plans to donate blood products within 28 days post study injection
Has participated in an investigational clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study
See 2 more
What Are the Treatments Tested in This Trial?
Interventions
- mRNA-1283
- mRNA-1273
Trial Overview The study is comparing the effectiveness and safety of two mRNA vaccines: mRNA-1283 and mRNA-1273. Some participants will receive a placebo instead. The goal is to determine if these vaccines can prevent COVID-19 in the specified age group without high-risk conditions.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Placebo Group
Group I: mRNA-1283 (Variant Formulation)Experimental Treatment1 Intervention
Participants will receive a single IM injection of mRNA-1283 on Day 1.
Group II: mRNA-1273 (Variant Formulation)Experimental Treatment1 Intervention
Participants will receive a single intramuscular (IM) injection of mRNA-1273 on Day 1.
Group III: PlaceboPlacebo Group1 Intervention
Participants will receive a single IM injection of placebo on Day 1.
Find a Clinic Near You
Who Is Running the Clinical Trial?
ModernaTX, Inc.
Lead Sponsor
Trials
127
Recruited
66,790,000+
Dr. Stephen Hoge
ModernaTX, Inc.
Chief Medical Officer
MD from Harvard Medical School
Stéphane Bancel
ModernaTX, Inc.
Chief Executive Officer since 2011
MBA from Harvard Business School, MSc in Engineering from École Centrale Paris
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.